Summary: Beta2-adrenergic receptor agonists have been used for years in the treatment of obstructive pulmonary diseases. Due to their relaxant effect on the bronchi, they reduce symptoms of dyspnea in patients suffering from asthma and chronic obstructive pulmonary disease. According to the duration of the effect, the drugs are divided into short-acting and long-acting. In the group of long-acting b2-adrenergic agonists (LABA), formoterol characterized by rapid action time can be used as a rescue drug to stop dyspnea attacks and in regular treatment. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends the use of bronchodilators including LABA, e.g. formoterol at every stage of COPD treatment as first-line treatment in monotherapy (GOLD AB) or as an alternative treatment in combined pharmacotherapy (GOLD CD). In the management of obstructive lung diseases, the inhalation method is preferred when administrating drugs. Aerosols are generated, among other things, by dry powder inhalers – DPI (an inhaler that generates an aerosol from a powdered form). The Aerolizer is one of the most frequently used DPIs in both technical and clinical research. The use of LABA including formoterol, administered via Aerolizer, reduces the occurrence of symptoms, improves exercise tolerance and quality of life in patients with obstructive pulmonary disease.